Incidence and determinants of bacterial infections in HIV-positive patients receiving anti-Pneumocystis carinii/Toxoplasma gondii primary prophylaxis within a randomized clinical trial

Journal of Acquired Immune Deficiency Syndromes

Volumn 27, Issue 1, 2001, Pages 49-55

  Murri, Rita ^a   Ammassari, Adriana ^a   Pezzotti, Patrizio ^b   Cingolani, Antonella ^a   De Luca, Andrea ^a   Pallavicini, Federico ^a   Grillo, Rita ^a   Antinori, Andrea ^c  

^a CATHOLIC UNIVERSITY   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Bacterial infections; Cotrimoxazole; Pneumocystis carinii; Primary prophylaxis

Indexed keywords

COTRIMOXAZOLE; MALOPRIM;

ADULT; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OTITIS; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUSITIS; TOXOPLASMA GONDII; TOXOPLASMOSIS;

EID: 0035330059     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200105010-00009     Document Type: Article

References (43)

1. Trends in infectious diseases and cancers among persons dying of HIV infection in the United States from 1987 to 1992
2. HIV-associated respiratory diseases
3. Changes in pathological findings at autopsy in AIDS cases for the last 15 years
4. Impact of bacterial pneumonia and Pneumocystis carinii pneumonia on human immunodeficiency virus disease progression
5. Bacterial pneumonia in adult populations with human immunodeficiency virus (HIV) infection
6. Drug smoking, Pneumocystis carinii pneumonia, and immunosuppression increase risk of bacterial pneumonia in human immunodeficiency virus-seropositive injection drug users
7. Bacterial pneumonia in persons infected with the human immunodeficiency virus
8. Respiratory disease trends in the pulmonary complications of HIV infection study cohort
9. Human immunodeficiency virus disease-related neutropenia and the risk of hospitalization for bacterial infection
10. Bacterial pneumonia in HIV-infected patients: Analysis of risk factors and prognostic indicators
11. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
12. A randomized trial of three anti-Pneumocystis agents in patients with advanced human immunodeficiency virus infection
13. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome
14. The effect of Pneumocystis carinii prophylaxis regimens on the incidence of bacterial infections in HIV-infected patients
15. Early chemoprophylaxis with trimethoprim-sulfamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: A randomised trial
16. Granulocyte colony-stimulating factor use is associated with decreased bacteremia and increased survival in neutropenic HIV-infected patients
17. Bacteremia in HIV-infected patients: Short-term predictors of mortality
18. Aerosolized pentamidine, cotrimoxazole, and dapsone-pyrimethamine for primary prophylaxis of P. carinii pneumonia and toxoplasmic encephalitis
19. In-vitro investigation of the antibacterial activity of agents which may be used for the oral treatment of lung infections in cystic fibrosis patients
20. A randomized trial of cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of P. carinii pneumonia (PCP) and toxoplasmic encephalitis (TE)
21. Efficacy of trimethoprim-sulfamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: A randomised controlled trial
22. Risk factors for community acquired pneumonia among persons infected with human immunodeficiency virus
23. Community-acquired bacteremia in HIV-positive patients: Protective benefit of co-trimoxazole
24. Effect of trimethoprim-sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis on bacterial illness, Pneumocystis carinii pneumonia, and death in persons with AIDS
25. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV
26. Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection
27. Discontinuing primary and secondary PCP prophylaxis in patients who have increased CD4 counts in response to antiretroviral therapy: Preliminary results ACTG 888
28. Emergence of trimethoprim-sulfamethoxazole resistance in the AIDS era
29. New and emerging etiologies for community-acquired pneumonia with implications for therapy: A prospective multicenter study of 359 cases
30. Prospective study of the aetiology and outcome of pneumonia in the community
31. Microbial etiology of acute pneumonia in hospitalized patients
32. Community-acquired pneumonia. A North American perspective
33. Nosocomial pneumonia guidelines. An international perspective
34. Use of antimicrobial agents and drug resistance
35. Nosocomial colonization and infection in persons infected with human immunodeficiency virus
36. Frequency and risk factors of infectious complications in neutropenic patients infected with HIV
37. Neutropenia and bacterial infection in acquired immunodeficiency syndrome
38. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: Results of a randomized, multicenter, controlled trial
39. Neutropenia is a risk factor for gram-negative bacillus bacteremia in human immunodeficiency virus-infected patients: Results of a nested case-control study
40. Guideline for prevention of nosocomial pneumonia
41. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy
42. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
43. The affordability of antiretroviral therapy in developing countries: What policymakers need to know